Key result
CDT plus anticoagulation cuts in-hospital mortality ~59% in intermediate-risk PE without excess major bleeding.
Why the study?
Data on the initial management of intermediate-risk (or submassive) pulmonary embolism were limited and conflicting.
Does catheter-directed thrombolysis plus systemic anticoagulation reduce mortality compared to systemic anticoagulation alone in patients with intermediate-risk pulmonary embolism?
Meta-Analysis (n=10,549)
Does catheter-directed thrombolysis plus systemic anticoagulation reduce mortality compared to systemic anticoagulation alone in patients with intermediate-risk pulmonary embolism?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“This study expands the evidence supporting CDT as first-line therapy for submassive PE, and more RCTs are indicated to confirm our findings.”
In patients with intermediate-risk pulmonary embolism, adding catheter-directed thrombolysis to systemic anticoagulation significantly reduces short- and long-term mortality without increasing the risk of major or minor bleeding.
There are limited and conflicting data on the initial management of intermediate-risk (or submassive) pulmonary embolism (PE). This study sought to compare the outcomes of catheter-directed thrombolysis (CDT) in combination with systemic anticoagulation (SA) to SA alone. A systematic search was conducted in MEDLINE, EMBASE, PubMed, and the Cochrane databases from inception to March 1, 2023 for studies comparing the outcomes of CDT + SA versus SA alone in intermediate-risk PE. The outcomes were in-hospital, 30-day, 90-day, and 1-year mortality; bleeding; blood transfusion; right ventricular recovery; and length of stay. Random-effects models was used to calculate the pooled incidence and risk ratios (RRs) with 95% confidence intervals (CIs). A total of 15 (2 randomized and 13 observational) studies with 10,549 (2,310 CDT + SA and 8,239 SA alone) patients were included. Compared with SA, CDT + SA was associated with significantly lower in-hospital mortality (RR 0.41, 95% CI 0.30 to 0.56, p <0.001), 30-day mortality (RR 0.34, 95% CI 0.18 to 0.67, p = 0.002), 90-day mortality (RR 0.34, 95% CI 0.17 to 0.67, p = 0.002), and 1-year mortality (RR 0.58, 95% CI 0.34 to 0.97, p = 0.04). There were no significant differences between the 2 cohorts in the rates of major bleeding (RR 1.39, 95% CI 0.72 to 2.68, p = 0.56), minor bleeding (RR 1.83, 95% CI 0.97 to 3.46, p = 0.06), and blood transfusion (RR 0.34, 95% CI 0.10 to 1.15, p = 0.08). In conclusion, CDT + SA is associated with significantly lower short-term and long-term all-cause mortality, without any differences in major/minor bleeding, in patients with intermediate-risk PE.
Journal, society, and media accounts. Useful signal, not independent expert judgment.
No takes yet. Share an insight, caveat, or question.
Balakrishna et al. (2023) conducted a meta-analysis in Intermediate-risk pulmonary embolism (n=10,549). Catheter-directed thrombolysis plus systemic anticoagulation vs. Systemic anticoagulation alone was evaluated on In-hospital mortality (RR 0.41, 95% CI 0.30-0.56, p=<0.001). Catheter-directed thrombolysis plus systemic anticoagulation lowered in-hospital mortality without increasing major bleeding in intermediate-risk PE.
Synapse has enriched 10 related papers. Consider them for comparative context: